Sleep & Menopause · Vespera Journal

The 3 a.m. problem nobody warned you about

What's actually happening, what your options are, and why your doctor probably didn't bring it up.

Sam Wilmar Founder, Vespera · Published 1 September 2026 · 7 min read

You fall asleep fine. That's the confusing part.

It's the waking that's new. Some time in the small hours, you're just — awake. Not groggy-awake. Wide awake, in a quiet house, with a mind that has decided this is a good moment to review everything.

By 6 a.m. you've either fallen back asleep for forty minutes or you haven't. Either way the day starts, and you get through it, and nobody at work can tell. And then it happens again.

This page is not going to tell you that's normal and you should ride it out. It's going to tell you what's known about it, what actually helps, and where the honest gaps are.

You're not imagining it

Among American women aged 40 to 59, more than half of those in perimenopause are sleeping under seven hours a night. That's the CDC's National Center for Health Statistics, from national survey data — not a supplement company's own survey.

Sleep problems across the menopause transition

US women aged 40–59, by menopausal status

Sleeps under 7 hours a night Trouble staying asleep, 4+ nights a week

60% 45% 30% 15% 0 Premenopausal · sleeps under 7 hours · 32.5% Premenopausal · trouble staying asleep · 23.7% 32.5 23.7 Perimenopausal · sleeps under 7 hours · 56.0% Perimenopausal · trouble staying asleep · 30.8% 56.0 30.8 Postmenopausal · sleeps under 7 hours · 40.5% Postmenopausal · trouble staying asleep · 35.9% 40.5 35.9 Premenopausal Perimenopausal Postmenopausal
View as table
StatusUnder 7 hrsTrouble staying asleep
Premenopausal32.5%23.7%
Perimenopausal56.0%30.8%
Postmenopausal40.5%35.9%
Source: Vahratian A, NCHS Data Brief No. 286 (2017), National Health Interview Survey.

Notice the two lines don't move together. Short sleep peaks in perimenopause and eases afterwards. But trouble staying asleep keeps climbing right through to postmenopause. For a lot of women, the waking doesn't stop when the periods do.

One honest note, because you'll see it stated more confidently elsewhere: the link between night sweats and waking up is less settled than it sounds. Some studies find hot flashes closely tracked with waking. One study that measured them objectively during sleep found the relationship largely disappeared — women reported hot flashes waking them, but the recordings suggested they were often already awake. If you've assumed the sweating is the whole story, the research isn't sure either.

How long this actually lasts

Here's the number most women aren't given. The Study of Women's Health Across the Nation followed 1,449 women with frequent symptoms and measured how long those symptoms ran.

7.4 years — the median duration of vasomotor symptoms. Median persistence after the final period: 4.5 years.

Median duration of vasomotor symptoms, by group

Years, among women with frequent symptoms (SWAN, n=1,449)

Black women · 10.1 years Hispanic women · 8.9 years White women · 6.5 years Asian women · about 5 years Black Hispanic White Asian 10.1 8.9 6.5 ~5 Overall median 7.4 0 4 yrs 8 yrs 12 yrs
View as table
GroupMedian duration
Black women10.1 years
Hispanic women8.9 years
White women6.5 years
Asian womenapprox. 5 years
Overall median7.4 years
Source: Avis NE et al., JAMA Internal Medicine 2015. The figure for Asian women is reported as approximate in the published summaries.

And if symptoms started early — while periods were still regular, or had only just begun changing — the median was more than 11.8 years, with 9.4 of those coming after the final period.

This matters for one practical reason. "Wait it out" is advice that gets handed out casually. For a median woman it means waiting out something closer to a presidential term than a rough season.

Why nobody told you

You may have assumed your doctor didn't raise it because it wasn't worth raising. Here's another explanation.

6.8% of US medical residents surveyed said they felt adequately prepared to manage women going through menopause. About one in five had received no menopause lectures at all.

That was 183 residents across family medicine, internal medicine and obstetrics and gynecology. A separate 2023 survey of OB/GYN residency programme directors found only 31% included menopause education in their training at all. Of those that did, 71% ran two or fewer lectures a year.

This isn't a conspiracy and it isn't your doctor's fault. It's a documented gap in medical education, and it's being written about by the people trying to close it. But it does mean that "my doctor didn't mention it" is not evidence that there's nothing to mention.

Most women are handling this alone

A 2025 Mayo Clinic study of nearly 5,000 women aged 45 to 60 found that more than 75% had menopause symptoms, and over half reported disrupted sleep.

80% had not sought medical care for their symptoms. Only about one in four were receiving any treatment at all.

So if you've been handling this by yourself, that isn't unusual. It's the majority experience.

What your options actually are

Before we tell you what we make, here's the honest landscape. Some of this is better than what we sell.

Hormone therapy The most effective option for vasomotor symptoms, and the guidance changed recently. In November 2025 the FDA announced the removal of the boxed warnings on menopausal hormone therapy, and in February 2026 approved updated labeling across six products. Important nuance: the risk information was moved out of the boxed warning, not deleted — this isn't a declaration that hormone therapy is risk-free. But if you were told years ago that it was off the table for you, that advice may be out of date, and it's worth a fresh conversation.
Non-hormonal prescriptions Two drugs are now FDA-approved specifically for moderate to severe hot flashes. Fezolinetant (Veozah), approved 2023 — it carries a boxed warning for liver injury and requires blood tests before starting and periodically after. Elinzanetant (Lynkuet), approved October 2025, taken at bedtime. Both are approved for hot flashes, not for insomnia.
Cognitive behavioral therapy for insomnia Under-known, and the evidence is strong. If you take one thing from this page and never buy anything from us, take this one.

Insomnia remission in postmenopausal women

Share reaching remission after treatment, randomised trial, n=150

60% 40% 20% 0 CBT for insomnia · 54% Sleep restriction therapy · 38% Sleep hygiene education · 4% 54% 38% 4% CBT for insomnia Sleep restriction Sleep hygiene advice
View as table
TreatmentRemission, post-treatmentAt 6 months
CBT for insomnia54%67.8%
Sleep restriction therapy38%55.8%
Sleep hygiene education4%13.3%
Source: Drake CL et al., Sleep 2019;42(2). At six months the CBT-I group was getting roughly 40 minutes more sleep a night than the other two.
Supplements and botanicals Which is what we make — so read the next part with that in mind.

Where we fit

More than 80% of women with these symptoms aren't getting any treatment at all. Most of them aren't choosing between our product and a prescription — they're choosing between something and nothing, often at 3 a.m., often without having had the conversation with a doctor that this page has just spent several paragraphs recommending.

If you want to try a herbal supplement, we think you should be able to see exactly what you're taking, in exactly what amount, and get your money back if it does nothing for you. That's the whole proposition.

Nightly is a herbal supplement. It is not a treatment for anything, and it is not a substitute for talking to a clinician.

What's in it

No proprietary blends. Every dose printed, because you should be able to look each one up yourself — including the ones you might not like.

NightlyTypical menopause blend
Every dose printedYesProprietary blend
Number of products to choose fromOneA range, with upsells
CapsuleBovine gelatin — not vegetarianOften unstated
Allergens named on the pageContains soyOn the bottle only
Who shouldn't take itListed belowRarely stated
Money back if it does nothing60 days, keep the bottleReturn unopened
Nightly Supplement Facts panel, listing every ingredient and its amount per serving
Every ingredient and its amount, exactly as it appears on the bottle. Two capsules per serving, 30 servings. Made in the USA in a GMP-certified facility.

Who shouldn't take this

Don't take Nightly, or talk to your doctor first, if any of these apply to you.

  • You have or have had a hormone-sensitive condition, including breast cancer. Nightly contains three sources of phytoestrogens — soy isoflavones, red clover and black cohosh. International guidance does not recommend these after breast cancer.
  • You take tamoxifen, warfarin or other blood thinners, hormonal contraception, or dopamine-affecting medication.
  • You have liver disease, or any history of liver problems. Black cohosh has been associated with rare cases of liver injury. Stop taking this and see a doctor if you develop abdominal pain, dark urine, or yellowing of the skin or eyes.
  • You're pregnant or breastfeeding.
  • You have a soy allergy.

If you're not sure, ask a pharmacist. It's free and it takes five minutes.

Try it for 60 days

If it does nothing for you, keep the bottle and we'll refund you. Not "return it unopened" — open it, take it, finish half of it. If you want your money back on your first order, email us and it's done.

We launched in September 2026. We don't have customer reviews yet. When we do, they'll be from verified purchases and we'll publish them unedited, good and bad. Until then, the guarantee is what we've got.

See exactly what's in Nightly →

Sources

  1. Vahratian A. Sleep Duration and Quality Among Women Aged 40–59, by Menopausal Status. NCHS Data Brief No. 286, 2017. cdc.gov
  2. Bianchi MT, et al. Nocturnal Hot Flashes: Relationship to Objective Awakenings and Sleep Stage Transitions. J Clin Sleep Med 2016;12(7):1003–1009.
  3. Avis NE, et al. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. JAMA Intern Med 2015;175(4):531–539. pubmed.ncbi.nlm.nih.gov
  4. Kling JM, et al. Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents. Mayo Clin Proc 2019;94(2):242–253. pubmed.ncbi.nlm.nih.gov
  5. Menopause education in OB/GYN residency programmes, survey 2023. pubmed.ncbi.nlm.nih.gov
  6. Kapoor E, et al. Addressing Menopause Symptoms: Barriers and Opportunities for Improvement. Mayo Clin Proc 2025. mayoclinicproceedings.org
  7. US Food and Drug Administration. FDA Approves Labeling Changes for Menopausal Hormone Therapy Products. 12 February 2026. fda.gov
  8. US Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant). fda.gov
  9. Lynkuet (elinzanetant) prescribing information, approved 24 October 2025. accessdata.fda.gov
  10. Drake CL, et al. Treating chronic insomnia in postmenopausal women: a randomized clinical trial. Sleep 2019;42(2):zsy217. academic.oup.com
  11. Baker FC, et al. Sleep problems during the menopausal transition. Nat Sci Sleep 2018;10:73–95.

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.